Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.24.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Cash, uninsured amount $ 100,000 $ 800,000
Cash equivalents 0 0
Inventory valuation reserves 9,500,000 21,400,000
Advertising expense 1,200,000 2,800,000
VAT payable $ 400,000 400,000
Indemnification assets, gain on recovery   $ 2,000,000.0
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage 21.00% 22.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage 11.00% 31.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage   17.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage   15.00%
IPO [Member] | Airgraft Inc [Member]    
Product Information [Line Items]    
Liability for returns included in accrued expenses $ 100,000 $ 300,000
IPO [Member] | Minimum [Member] | Airgraft Inc [Member]    
Product Information [Line Items]    
Total order cost, percentage 25.00%  
IPO [Member] | Maximum [Member] | Airgraft Inc [Member]    
Product Information [Line Items]    
Total order cost, percentage 50.00%